Real-World Outcomes of Direct-Acting Antiviral Treatment and Retreatment in United Kingdom–Based Patients Infected With Hepatitis C Virus Genotypes/Subtypes Endemic in Africa( )

BACKGROUND: Chronic hepatitis C virus (HCV) infection affects 71 million individuals, mostly residing in low- and middle-income countries (LMICs). Direct-acting antivirals (DAAs) give high rates of sustained virological response (SVR) in high-income countries where a restricted range of HCV genotype...

Descripción completa

Detalles Bibliográficos
Autores principales: Aranday-Cortes, Elihu, McClure, C Patrick, Davis, Christopher, Irving, William L, Adeboyejo, Kazeem, Tong, Lily, da Silva Filipe, Ana, Sreenu, Vattipally, Agarwal, Kosh, Mutimer, David, Stone, Benjamin, Cramp, Matthew E, Thomson, Emma C, Ball, Jonathan K, McLauchlan, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492310/
https://www.ncbi.nlm.nih.gov/pubmed/33668068
http://dx.doi.org/10.1093/infdis/jiab110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492310/
https://www.ncbi.nlm.nih.gov/pubmed/33668068
http://dx.doi.org/10.1093/infdis/jiab110

Ejemplares similares